522 related articles for article (PubMed ID: 24976077)
21. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
22. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
[TBL] [Abstract][Full Text] [Related]
23. Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer.
Li J; Ren S; Piao HL; Wang F; Yin P; Xu C; Lu X; Ye G; Shao Y; Yan M; Zhao X; Sun Y; Xu G
Sci Rep; 2016 Feb; 6():20984. PubMed ID: 26865432
[TBL] [Abstract][Full Text] [Related]
24. Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (
Fredsøe J; Rasmussen AKI; Laursen EB; Cai Y; Howard KA; Pedersen BG; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
Clin Chem; 2019 Apr; 65(4):540-548. PubMed ID: 30728149
[TBL] [Abstract][Full Text] [Related]
25. Potential plasma microRNAs signature miR-190b-5p, miR-215-5p and miR-527 as non-invasive biomarkers for prostate cancer.
Khan MM; Serajuddin M; Bharadwaj M
Biomarkers; 2023 Mar; 28(2):227-237. PubMed ID: 36644827
[No Abstract] [Full Text] [Related]
26. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification.
Al-Kafaji G; Said HM; Alam MA; Al Naieb ZT
Oncol Lett; 2018 Jul; 16(1):1357-1365. PubMed ID: 30061955
[TBL] [Abstract][Full Text] [Related]
27. miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer.
Karatas OF; Guzel E; Suer I; Ekici ID; Caskurlu T; Creighton CJ; Ittmann M; Ozen M
PLoS One; 2014; 9(6):e98675. PubMed ID: 24967583
[TBL] [Abstract][Full Text] [Related]
28. A circulating miRNA assay as a first-line test for prostate cancer screening.
Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
[TBL] [Abstract][Full Text] [Related]
29. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
Fu S; Zhang X; Niu Y; Wang RT
Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
[TBL] [Abstract][Full Text] [Related]
30. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
31. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA
Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Value of Peripheral Blood miR-374b-5p in Patients with Prostate Cancer.
Pang C; Song X; Fu C; Zhang Y; Zhang Y; Liu M
Clin Lab; 2020 Jan; 66(1):. PubMed ID: 32013356
[TBL] [Abstract][Full Text] [Related]
34. Analysis of circulating miRNAs 21 and 375 as potential biomarkers for early diagnosis of prostate cancer.
Gao Y; Guo Y; Wang Z; Dai Z; Xu Y; Zhang W; Liu Z; Li S
Neoplasma; 2016; 63(4):623-8. PubMed ID: 27268927
[TBL] [Abstract][Full Text] [Related]
35. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
[TBL] [Abstract][Full Text] [Related]
36. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role.
Cochetti G; Poli G; Guelfi G; Boni A; Egidi MG; Mearini E
Onco Targets Ther; 2016; 9():7545-7553. PubMed ID: 28008272
[TBL] [Abstract][Full Text] [Related]
37. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
[TBL] [Abstract][Full Text] [Related]
38. [Differentially expressed genes in prostate cancer and benign prostatic hyperplasia].
Zhang T; Xu Y; Tang H; Liu M; Ren D; Niu Y
Zhonghua Nan Ke Xue; 2004 Dec; 10(12):897-9. PubMed ID: 15638016
[TBL] [Abstract][Full Text] [Related]
39. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
[TBL] [Abstract][Full Text] [Related]
40. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T
Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
